Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Public ClinicalTrials.gov record NCT02214628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the Induction and Maintenance Phase of Therapy
Study identification
- NCT ID
- NCT02214628
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ophthotech Corporation
- Industry
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Nov 30, 2016
- Completion
- Nov 30, 2016
- Last update posted
- Feb 22, 2024
2014 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85014 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Sacramento | California | 95819 | — |
| Not listed | Sacramento | California | 95841 | — |
| Not listed | Santa Ana | California | 92705 | — |
| Not listed | Augusta | Georgia | 30909 | — |
| Not listed | Oak Forest | Illinois | 60452 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Jackson | Michigan | 49202 | — |
| Not listed | Minneapolis | Minnesota | 55435 | — |
| Not listed | Cincinnati | Ohio | 45242 | — |
| Not listed | Ladson | South Carolina | 29456 | — |
| Not listed | Abilene | Texas | 79606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02214628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02214628 live on ClinicalTrials.gov.